评估他汀类药物使用与选择主动监测的局限性前列腺癌男性肿瘤学结局之间的关系
这项回顾性队列研究纳入2005至2015年在一家大型学术医疗中心接受主动监测的635例男性,评估他汀治疗对疾病再分类、进展至根治性治疗和监测失败的影响。结果显示他汀使用与上述结局均无关联,但在进展至根治性前列腺切除术的105例男性中,他汀使用时长与不良病理风险降低相关。
要点
- 635例主动监测男性中356例(56.1%)在监测开始时使用他汀。
- 他汀与非他汀使用者的疾病再分类、进展至根治性治疗和监测失败率均无差异(所有p>0.05)。
- 在105例进展至根治性前列腺切除术的男性中,他汀使用时长与不良病理风险降低相关(多因素OR:0.98;95%CI 0.97, 0.99;p=0.02)。
核心结论
- 他汀使用与疾病再分类、进展至根治性治疗或监测失败方面无临床获益。
- 在进展至根治性前列腺切除术的男性中,他汀使用每增加一个月,不良病理的比值降低2%,但该关联对监测结局是否有持久影响尚不清楚。
研究设计与样本
- 这是一项回顾性队列研究,评估2005年至2015年在一家大型学术医疗中心接受主动监测的635例男性。
主要发现
- 356例(56.1%)患者在监测开始时使用他汀。
- 他汀使用者中位年龄为66.7岁,非他汀使用者中位年龄为63.3岁。
- 单因素分析显示,他汀与非他汀使用者在疾病再分类、进展至根治性治疗和监测失败率方面均无差异(所有p>0.05)。
- 在进展至根治性治疗的男性中,按他汀使用分层,生化失败率无差异(p=0.89)。
- 在本机构监测期间进展至根治性前列腺切除术的105例男性中,他汀使用时长(月)与不良病理呈负相关,单因素分析OR:0.99(95%CI 0.98, 0.99;p=0.03),多因素分析OR:0.98(95%CI 0.97, 0.99;p=0.02)。
关键数值与推荐
- 主要终点为疾病再分类(即诊断后后续活检中癌症体积或分级的变化)、进展至根治性治疗(即手术或放疗)和监测失败(定义为根治性治疗后生化失败、转移或前列腺癌特异性死亡)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study aims to assess the effect of statin therapy on outcomes among men managed with active surveillance. METHODS: This is a retrospective cohort study evaluating 635 men managed with active surveillance from 2005 to 2015 at a large, academic medical center. The primary endpoints of analyses are disease reclassification (i.e., change in volume or grade of cancer on subsequent biopsies after diagnosis), progression to definitive therapy with curative intent (i.e., surgery or radiotherapy), and surveillance failure-defined as the development of either biochemical failure after definitive therapy, metastases, or prostate cancer-specific mortality-among statin and non-statin users. Secondary analyses were performed to assess the effect of statin use on outcomes among men who progressed to definitive treatment. RESULTS: Three hundred fifty-six (56.1%) patients in the cohort were on statin therapy at the initiation of surveillance. The median age was 66.7 and 63.3 years among statin and non-statin users, respectively. On univariate analysis, there were no differences in the rates of disease reclassification, progression to definitive treatment, and surveillance failure between the statin and non-statin users in the cohort (all p > 0.05). There was no difference in the rate of biochemical failure among men who progressed to definitive therapy when stratified by statin use (p = 0.89). Pathologic data were available for 105 men who progressed to radical prostatectomy while on surveillance at our institution. Duration of statin use (months) was inversely correlated with adverse pathology for radical prostatectomy on both univariate (OR: 0.99; 95% CI 0.98, 0.99; p = 0.03) and multivariate analysis (OR: 0.98; 95% CI 0.97, 0.99; p = 0.02). CONCLUSION: Statin use was not associated with any clinical benefit with regard to disease reclassification, progression to definitive treatment, or surveillance failure among men selecting active surveillance at our institution. There was a 2% decrease in the odds of adverse pathology for each month of statin use among the men who progressed to radical prostatectomy while on active surveillance, but it is unclear at this time if this association has any durable impact on surveillance outcomes among men with favorable risk prostate cancer.
引用
- Nyame YA, Wilkins L, Greene DJ, et al. Assessing the relationship between statin use and oncologic outcomes among men electing active surveillance for localized prostate cancer. Prostate Cancer Prostatic Dis. 2019. PMID: 30996285. doi:10.1038/s41391-019-0147-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。